The four peptides with the strongest research rationale for longevity in 2026 are NAD+ precursors, GHK-Cu, MOTS-C, and Epithalon. Each targets a distinct cellular pathway, from sirtuin activation to telomere regulation. In the UK all four are supplied strictly for laboratory research, with no MHRA marketing authorisation for human use.
| Peptide | Primary mechanism | Delivery format | UK availability |
|---|---|---|---|
| NAD+ (NMN/NR) | Sirtuin activation, DNA repair | Oral, IV, sublingual | Widely available |
| GHK-Cu | Extracellular matrix remodelling, collagen signalling | Topical, injectable vial | Research suppliers |
| MOTS-C | Mitochondrial metabolic signalling | Lyophilised vial | Research suppliers |
| Epithalon | Telomerase induction, pineal peptide | Lyophilised vial | Research chemical |
A 2023 Nature systems-biology trial found that NAD+ repletion raised whole-blood NAD+ and was associated with a 1.26-year reduction in an IgG-glycosylation-based biological-age measure. NAD+ availability constrains sirtuin activity during ageing, which is why it anchors most UK longevity stacks. The sections below cover each peptide's dosing, format, and sourcing in detail.
Last updated: 2026
Key Takeaways
- NAD+ precursors (NMN, NR) support sirtuin-linked DNA repair and are the most mechanistically grounded longevity peptide available in the UK
- GHK-Cu targets extracellular matrix remodelling and collagen synthesis, making it relevant to tissue-repair research
- MOTS-C is a mitochondria-derived peptide investigated for metabolic flexibility and insulin sensitivity
- Epithalon is studied for telomerase activation but remains a research chemical with limited UK availability
- Pre-filled pen formats offer better stability, reduced contamination risk, and dosing precision compared to lyophilised vials
Why Peptides Matter for Longevity Research
Longevity peptides are short-chain amino acid sequences, typically 2 to 50 residues, that bind specific cellular receptors or enzymes to modulate discrete ageing pathways, mitochondrial energy metabolism, extracellular matrix repair, metabolic flexibility, and telomere maintenance.
Precision targeting over broad-spectrum supplementation
Peptides sit in a practical middle ground between small-molecule drugs and full-length proteins. Their low molecular weight improves tissue penetration and oral or subcutaneous bioavailability, while their short sequence length reduces the immunogenic risk associated with larger biologics. That combination makes them tractable for research into specific ageing mechanisms rather than systemic, poorly characterised interventions.
Each peptide in this list maps to a distinct pathway. NAD+ precursors support sirtuin-linked DNA repair and redox signalling, NAD+ availability is a documented constraint on sirtuin activity during ageing. GHK-Cu, a copper-binding tripeptide, is associated with extracellular matrix remodelling and collagen-related signalling, making it a subject of skin longevity studies. MOTS-C is a mitochondria-derived peptide investigated for effects on insulin sensitivity and metabolic homeostasis; its exercise-mimetic signalling profile also connects it to muscle growth and metabolic fitness research. Epithalon, a synthetic tetrapeptide derived from the pineal gland, is studied for telomerase induction.
What the current evidence supports
A 2023 Nature systems-biology trial reported that NAD+ repletion raised whole-blood NAD+ and was associated with a 1.26-year reduction in an IgG-glycosylation-based biological-age measure. NAD+ is a rate-limiting substrate for sirtuin-dependent DNA repair in aged tissue. The mechanistic literature on GHK-Cu and MOTS-C is promising, but human clinical data remain limited. Claims about collagen-induction magnitude and metabolic flexibility in aged cohorts are unverified from current primary sources. Researchers sourcing these compounds in the UK should treat the evidence base as mechanistically credible but not yet clinically validated for anti-ageing endpoints.
Best Longevity Peptides: UK 2026 Comparison Table
The four peptides below represent distinct, mechanistically grounded targets in longevity research. Each row maps to a specific biological pathway, a typical research dose, and the delivery format available from UK suppliers as of 2026.
| Peptide | Primary Mechanism | Typical Research Dose | Delivery Format | UK Availability |
|---|---|---|---|---|
| NAD+ | Sirtuin-linked DNA repair and redox signalling; NAD+ availability is a documented constraint on sirtuin activity during ageing | 10, 20, or 30 mg (selectable per dose) | Pre-filled pen | Available from UK-based research suppliers |
| GHK-Cu | Copper-binding tripeptide associated with extracellular matrix remodelling and collagen-related signalling; studied in skin longevity research | 50 mg pre-mixed | Pre-filled pen | Available from UK-based research suppliers |
| MOTS-C | Mitochondria-derived 16-amino-acid peptide investigated for insulin sensitivity, metabolic homeostasis, and exercise-mimetic signalling; relevant to muscle growth and metabolic fitness research | 32-dose pen format | Pre-filled pen | Available from UK-based research suppliers |
| Epithalon | Synthetic tetrapeptide studied for telomerase induction and telomere-length maintenance | 10 mg per vial | Lyophilised vial | Treated as a research chemical in the UK; no mainstream licensed pharmacy availability |
Why these four
NAD+ is the rate-limiting substrate for sirtuin-dependent DNA repair in aged tissue. GHK-Cu and MOTS-C are included for their tissue-repair and metabolic-flexibility profiles respectively, with pen-format delivery offering dosing precision that lyophilised vials require the researcher to calculate manually. Epithalon's vial format reflects its status as a research chemical rather than an authorised medicine. Sourcing requires careful supplier vetting given the absence of MHRA-licensed UK pharmacy routes.
NAD+ Peptide Pens: Cellular Energy and Mitochondrial Function
NAD+ (nicotinamide adenine dinucleotide) is the rate-limiting coenzyme for sirtuin activation and ATP (adenosine triphosphate) synthesis, and its whole-body concentration falls measurably across the human lifespan.
The mechanism behind the research interest
Sirtuins (SIRT1βSIRT7) are NAD+-dependent deacylases that regulate DNA repair, mitochondrial biogenesis, and inflammatory signalling. Without sufficient NAD+, sirtuin activity is constrained regardless of how well the downstream pathways are expressed. A 2023 systems-based trial published in Nature found that a multi-component NAD+ supplement raised whole-blood NAD+ and was associated with a 1.26-year reduction in an IgG-glycosylation-derived biological-age measure in a small crossover cohort. That figure comes from a single trial and should not be extrapolated to population-level efficacy, but it illustrates why NAD+ repletion remains an active research focus rather than a speculative one.
Free NAD+ is poorly stable in circulation. Precursor molecules such as NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are more bioavailable delivery vehicles, and formulation quality directly affects how much active coenzyme reaches target tissue.
Why the pen format changes the dosing calculus
The 1,000 mg NAD+ pre-filled pen offers three selectable dose increments: 10 mg, 20 mg, or 30 mg per administration. That translates to 100 doses at the 10 mg setting, 50 doses at 20 mg, or 33 doses at 30 mg from a single pen. Researchers can therefore adjust the protocol without preparing a new vial or recalculating reconstitution volumes.
Lyophilised vials require the researcher to reconstitute with bacteriostatic water, calculate concentration per draw, and use the resulting solution within a defined window before oxidation degrades potency. The pen format removes each of those steps. The pre-mixed solution is sealed against atmospheric oxygen, and the fixed-increment dial removes the arithmetic that introduces dosing error in vial-based protocols.
Contextualising NAD+ within a broader longevity stack
NAD+ research sits primarily in the cellular energy and DNA-integrity space. MOTS-C, by contrast, is investigated for mitochondrial metabolic signalling and insulin sensitivity, a complementary but mechanistically distinct pathway. The hypothesis that the two act additively across redox and metabolic axes is plausible given their separate targets, though no peer-reviewed trial has validated a combined protocol. Researchers interested in the metabolic side of that pairing may find the best peptides for muscle growth overview useful for MOTS-C context, while GHK-Cu's role in extracellular matrix signalling is covered in the best peptides for skin section.
GHK-Cu Copper Tripeptide: Collagen and Tissue Regeneration
GHK-Cu (glycine-histidine-lysine copper complex) is a signalling peptide that upregulates collagen I, III, and IV synthesis, supports wound repair, and increases dermal thickness. That makes it one of the more mechanistically grounded peptides in age-related tissue research.
How GHK-Cu acts on ageing tissue
The peptide binds copper ions and presents them to fibroblasts, triggering a downstream signalling cascade that promotes extracellular matrix remodelling. In ageing skin, collagen density declines progressively from the third decade onward. GHK-Cu's fibroblast-activating mechanism targets that deficit directly. Research protocols typically use 2β5 mg per application, a range narrow enough that dosing precision matters considerably.
Dermal thickness is a measurable correlate of biological skin age, and GHK-Cu's role in maintaining it positions the peptide as relevant beyond cosmetic interest. Researchers tracking visible markers of cellular longevity will find further context in the best peptides for skin overview, which covers GHK-Cu alongside other collagen-pathway compounds.
Why the pre-mixed pen format matters here
The 50 mg pre-mixed pen removes reconstitution entirely. With lyophilised GHK-Cu, the researcher must dissolve the powder in bacteriostatic water and use the resulting solution before oxidation degrades the copper-peptide bond. This bond is sensitive to pH shift and atmospheric exposure. The pre-mixed format seals the solution against oxygen ingress and maintains consistent copper-peptide binding from the first dose to the last.
Contamination risk drops significantly. Every reconstitution step introduces a potential point of failure: needle penetration of a septum, syringe handling, and transfer between vessels. The pen bypasses all of those steps with a single-use tip and a sealed cartridge.
At the 2β5 mg research dose range, the 50 mg pen yields between 10 and 25 administrations, a practical run length for a structured tissue-regeneration protocol without mid-course reformulation.
GHK-Cu at a glance
| Parameter | Detail |
|---|---|
| Peptide class | Copper-binding tripeptide |
| Primary research targets | Collagen I, III, IV synthesis; wound repair; dermal thickness |
| Typical research dose | 2β5 mg per application |
| Pen format | 50 mg pre-mixed, sealed cartridge |
| Stability advantage | Copper-peptide bond preserved; no reconstitution oxidation risk |
GHK-Cu activates fibroblast-mediated collagen synthesis and extracellular matrix remodelling in ageing tissue. Researchers combining tissue-regeneration and metabolic protocols may also find the best peptides for muscle growth page relevant, given the overlap between connective tissue integrity and exercise-capacity outcomes in longevity research.
MOTS-C: Mitochondrial Peptide for Metabolic Flexibility
MOTS-C is a 16-amino-acid peptide encoded within mitochondrial DNA, specifically the 12S rRNA (ribosomal RNA) gene. It regulates metabolic homeostasis, glucose uptake, and exercise-like signalling pathways in ageing tissue.
Unlike peptides synthesised in the cytoplasm, MOTS-C originates inside the mitochondria and acts as an intracellular messenger. It translocates to the nucleus under metabolic stress to modulate gene expression linked to insulin sensitivity and fatty acid oxidation. That origin gives it a mechanistic profile distinct from growth-factor peptides. Its primary target is mitochondrial function and the metabolic flexibility that declines with age.
Why metabolic flexibility matters in ageing research
Metabolic flexibility, the capacity to switch efficiently between glucose and fatty acid oxidation, deteriorates progressively from the fifth decade onward. That deterioration is associated with sarcopenia, impaired exercise recovery, and dysregulated glucose homeostasis. MOTS-C is being investigated as a peptide that may support mitochondrial biogenesis and partially restore this switching capacity, making it particularly relevant to age-related metabolic decline and muscle-preservation research. Researchers working on sarcopenia protocols may find it useful alongside the peptides covered on the best peptides for muscle growth page, where exercise capacity and lean-mass outcomes intersect with metabolic signalling.
The current evidence supports MOTS-C's role in metabolic adaptation research, though human clinical data confirming efficacy in age-related metabolic dysfunction remains limited. Claims beyond research interest are not yet warranted.
MOTS-C at a glance
| Parameter | Detail |
|---|---|
| Peptide class | Mitochondria-derived peptide (MDP) |
| Amino acid length | 16 amino acids |
| Encoding locus | Mitochondrial 12S rRNA gene |
| Primary research targets | Insulin sensitivity, glucose homeostasis, mitochondrial biogenesis, exercise capacity |
| Typical research dose | 10 mg per administration |
| Pen format | 32-dose pre-filled pen (320 mg total) |
| Relevance to ageing | Age-related metabolic inflexibility; sarcopenia research |
The 32-dose pen at 10 mg per dose provides a structured run length suited to metabolic protocols without requiring mid-course reconstitution. At that dose interval, a single pen covers approximately four to eight weeks depending on administration frequency, a practical window for observing metabolic adaptation markers in a research setting.
Epithalon (Epitalon): Telomere Support and Cellular Senescence
Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) derived from the pineal gland extract Epithalamin. It is studied primarily for its capacity to activate telomerase and support telomere maintenance in ageing cells.
The telomere-ageing hypothesis holds that progressive telomere shortening across cell divisions drives cells into senescence, a state where they cease dividing, accumulate, and contribute to tissue dysfunction. Telomerase, the enzyme that rebuilds telomere sequences, is largely silenced in somatic cells after early development. Epithalon is investigated as a peptide that may partially reactivate this enzyme, potentially extending replicative lifespan in cell models. That mechanism makes it one of the more conceptually direct peptides in longevity research, though human clinical evidence confirming telomere-length outcomes remains limited.
Telomerase activation carries a recognised dual-edged implication in cancer biology. The same pathway that extends replicative capacity in healthy cells is exploited by malignant cells. For this reason, Epithalon is used exclusively in controlled research settings rather than general supplementation contexts.
In the UK, Epithalon is less readily available than NAD+ precursors or GHK-Cu. It is typically supplied as a lyophilised powder in 10 mg vials requiring reconstitution before use. Typical research doses range from 5 mg to 10 mg per administration. Unlike the pre-filled pen formats available for other peptides covered here, vial-based Epithalon demands careful sterile handling and cold-chain storage, factors that narrow its practical use to structured laboratory or clinical research environments. Sourcing requires thorough supplier vetting given the absence of mainstream licensed UK pharmacy availability.
Epithalon at a glance
| Parameter | Detail |
|---|---|
| Peptide class | Synthetic tetrapeptide |
| Sequence | Ala-Glu-Asp-Gly |
| Primary research target | Telomerase activation; telomere maintenance |
| Typical research dose | 5β10 mg per administration |
| UK formulation | Lyophilised powder, 10 mg vials |
| Delivery format | Vial (reconstitution required) |
| Availability in UK | Limited; research-chemical sourcing only |
| Key research caveat | Telomerase activation has dual implications in cancer biology |
How to Choose the Right Longevity Peptide for Your Research
Your research focus determines which peptide to prioritise. The four peptides covered here each target a distinct biological pathway, and selecting the wrong one for your protocol wastes both resources and data quality.
Decision framework by research target
| Research Focus | Peptide | Delivery Format |
|---|---|---|
| Mitochondrial energy and NAD+-dependent sirtuin signalling | NAD+ precursor peptide | Pre-filled pen |
| Tissue repair, extracellular matrix remodelling, collagen signalling | GHK-Cu | Pre-filled pen |
| Metabolic flexibility, insulin sensitivity, exercise-like signalling | MOTS-C | Pre-filled pen |
| Telomere maintenance and telomerase activation | Epithalon | Lyophilised vial |
NAD+ availability constrains sirtuin activity during ageing, making NAD+-focused protocols the most mechanistically grounded starting point for researchers interested in cellular energy and DNA repair. GHK-Cu suits protocols examining tissue-level outcomes, its copper-binding activity links directly to wound repair and matrix remodelling pathways. For metabolic research, MOTS-C is the appropriate selection; it is being investigated for effects on insulin sensitivity and metabolic homeostasis, areas that overlap with best peptides for muscle growth research given that exercise capacity is a recognised longevity marker. GHK-Cu's collagen-related signalling also connects to best peptides for skin, where cellular longevity has a measurable surface expression.
On peptide stacking
Combining NAD+ precursors with MOTS-C is common in longevity research protocols, with the rationale that redox balance and mitochondrial metabolic adaptation operate through complementary rather than identical pathways. That mechanistic logic is plausible, but no peer-reviewed trial as of 2026 has confirmed a validated synergistic outcome from this specific combination. Stacking should be approached as a hypothesis-testing exercise with careful dosing records and baseline biomarker monitoring, not as an established regimen. Epithalon is typically run as a standalone protocol given its telomerase-activation mechanism and the additional monitoring that warrants.
Peptide Delivery Formats: Pens vs. Vials in 2026
Pre-filled peptide pens now represent the standard delivery format in UK research settings. They offer no-reconstitution convenience, reduced contamination risk, and factory-calibrated dosing precision that lyophilised vials cannot match at the point of use.
| Format | Examples | Doses per unit | Reconstitution | Storage |
|---|---|---|---|---|
| Pre-filled pen | NAD+ 1,000 mg pen | 100 Γ 10 mg | None required | Per manufacturer cold-chain spec |
| Pre-filled pen | GHK-Cu 50 mg pen | Pre-mixed, variable | None required | Per manufacturer cold-chain spec |
| Pre-filled pen | MOTS-C pen | 32 doses | None required | Per manufacturer cold-chain spec |
| Lyophilised vial | Epithalon vial | Protocol-dependent | Sterile water required | Refrigeration; use within validated window |
Why format matters for peptide integrity
GHK-Cu is particularly sensitive to oxidation once copper is introduced into solution. Pre-mixed pen formats control that exposure window at manufacture, under validated conditions, rather than leaving it to the researcher's bench. For NAD+ and MOTS-C, the pen format removes the sterile-water reconstitution step entirely, reducing the variables that affect dose accuracy and sterility in practice.
Lyophilised vials remain appropriate for Epithalon, where the peptide is typically sourced as a research chemical and pre-filled pen formats are not yet widely available from vetted UK suppliers. Vial-based protocols require refrigeration, careful reconstitution technique, and use within the manufacturer's validated stability window, none of which is standardised across suppliers. Shelf-life claims for any format should be verified against the specific product's batch documentation rather than assumed from peptide class alone.
The MOTS-C pen's 32-dose configuration suits the structured dosing intervals used in metabolic research, where consistency across administrations matters for tracking outcomes linked to exercise capacity, a recognised longevity marker explored further in best peptides for muscle growth protocols. GHK-Cu's pre-mixed pen format similarly supports the collagen-related signalling research discussed in best peptides for skin, where dosing reproducibility affects the interpretability of any observed outcome.
UK Sourcing and Quality Standards for Longevity Peptides
Research peptides sold in the United Kingdom are classified for laboratory use only and carry no MHRA (Medicines and Healthcare products Regulatory Agency) authorisation for human administration. Sourcing from suppliers who provide verifiable third-party analytical data is the baseline requirement for any reproducible longevity research protocol.
What reputable UK suppliers provide
As of 2026, established UK suppliers such as Body Pharm supply each batch with HPLC (high-performance liquid chromatography) purity certificates and mass spectrometry validation, with purity guarantees typically stated at β₯98%. Batch certificates should include the specific lot number, test date, and the analytical method used, not a generic class-level claim. Batch-to-batch consistency is a direct variable in research reproducibility. A peptide at 94% purity in one order and 99% in the next introduces confounds that make outcome tracking unreliable.
Epithalon sits in a more constrained position than pen-format peptides. It is not available through mainstream licensed UK pharmacies and must be sourced as a research chemical, which places the burden of supplier vetting entirely on the researcher. Import rules and the absence of MHRA-assessed product listings mean that documentation scrutiny (certificate of analysis, country of manufacture, cold-chain records) is non-negotiable rather than optional.
Why purity data matters for longevity protocols
Longevity research depends on consistent dosing across extended observation windows. A purity shortfall of even a few percentage points alters the effective dose delivered per administration, which compounds across a multi-week protocol. JCSG's structural genomics resources illustrate the precision standards applied in institutional peptide research, a useful reference point for the documentation rigour that serious longevity work requires.
For peptides linked to metabolic outcomes, such as those explored in best peptides for muscle growth protocols, and for collagen-related research covered in best peptides for skin contexts, analytical consistency is what separates interpretable data from noise.
Longevity Peptides and Ageing Pathways: The Science
The 2023 updated hallmarks of ageing framework identifies twelve discrete biological failure modes, from mitochondrial dysfunction and telomere attrition to disabled macroautophagy and chronic inflammation. Each peptide covered in this article maps to at least one of them with mechanistic specificity.
| Peptide | Primary Hallmark Targeted | Proposed Mechanism |
|---|---|---|
| NAD+ precursors | Mitochondrial dysfunction; cellular senescence | NAD+ availability constrains sirtuin activity during ageing; repletion supports redox balance and DNA repair signalling |
| GHK-Cu | Loss of proteostasis; altered intercellular communication | Copper-binding tripeptide associated with extracellular matrix remodelling and wound-repair signalling |
| MOTS-C | Deregulated nutrient sensing; metabolic dysfunction | Mitochondria-derived peptide investigated for insulin sensitivity and exercise-like metabolic adaptation |
| Epithalon | Telomere attrition | Tetrapeptide studied for telomerase-related activity in ageing cell models |
NAD+ and sirtuin-linked pathways
NAD+ is a rate-limiting cofactor for sirtuin deacylases, which regulate gene expression, mitochondrial biogenesis, and DNA damage response. A 2023 Nature paper reported that a systems-based NAD+ supplement raised whole-blood NAD+ and was associated with a 1.26-year reduction in an IgG-glycosylation-based biological-age measure in a small crossover trial. The mechanistic literature is consistent: NAD+ availability declines with age and constrains sirtuin function, though human lifespan extension has not been demonstrated.
GHK-Cu, MOTS-C, and complementary targets
GHK-Cu operates downstream of tissue injury signals, modulating collagen-related gene expression and extracellular matrix remodelling. Its relevance extends beyond cosmetic outcomes, researchers studying best peptides for skin use it as a marker of cellular repair capacity. MOTS-C targets a distinct hallmark: deregulated nutrient sensing. Encoded in mitochondrial DNA, it is studied for its role in metabolic homeostasis and insulin sensitivity, pathways that also intersect with best peptides for muscle growth research, where metabolic flexibility is a direct performance variable.
Epithalon and telomere biology
Epithalon is a tetrapeptide investigated for telomerase-related activity. Telomere attrition is one of the most structurally well-characterised hallmarks of ageing, and Epithalon's proposed mechanism, stimulating telomerase expression in ageing cell models, places it at that specific node. NAD+ is a rate-limiting substrate for sirtuin-dependent DNA repair. A systems-based NAD+ intervention raised whole-blood NAD+ and produced a measurable shift in a glycosylation-based biological-age proxy in a 2023 peer-reviewed crossover trial.
Common Questions About Longevity Peptides
Five questions come up repeatedly among UK researchers sourcing these compounds. The answers below address each directly, with dose calculations and sourcing context where the data supports it.
| Question | Short Answer |
|---|---|
| Can I stack longevity peptides? | Yes, but timing and dosing matter |
| How long does a peptide pen last? | Depends on dose per use |
| Are pens more stable than vials? | Generally yes |
| What's the difference between NAD+ and NMN? | NAD+ is the active coenzyme; NMN is a precursor |
| Is Epithalon available in the UK? | Yes, via specialist suppliers |
Can I stack longevity peptides?
NAD+ and MOTS-C are a commonly paired combination because they target distinct but complementary pathways. NAD+ repletion supports sirtuin-linked signalling and redox balance, while MOTS-C is studied for mitochondrial metabolic adaptation. No 2024β2026 primary research has validated a specific stacked protocol, so the rationale remains mechanistically additive rather than clinically proven. Run each compound at its established research dose rather than reducing either to accommodate the other.
How long does a peptide pen last?
The calculation is straightforward: a 1,000 mg NAD+ pen dosed at 10 mg per administration yields 100 doses. At five doses per week, that is a 20-week supply from a single pen. Dose per use is the only variable that changes this figure, so confirm the per-actuation volume before purchasing.
Are peptide pens more stable than vials?
Pre-filled pens reduce two primary degradation risks: oxidation from repeated air exposure and contamination from manual reconstitution. Lyophilised vials offer storage robustness before reconstitution, but once a vial is opened and reconstituted, the stability window narrows considerably. The definitive answer for any specific product depends on the manufacturer's validated stability data and cold-chain requirements, not a general rule across peptide classes.
What is the difference between NAD+ and NMN?
NAD+ is the active coenzyme that sirtuins and PARP (poly-ADP-ribose polymerase) enzymes require directly. NMN is a biosynthetic precursor that the body converts to NAD+. Oral NAD+ has poor bioavailability due to gut degradation. NMN's smaller molecular structure gives it better absorption via the oral route. A 2023 crossover trial using a systems-based NAD+ formulation raised whole-blood NAD+ and was associated with a 1.26-year reduction in a glycosylation-based biological-age measure, suggesting that delivery format matters as much as the compound itself.
Is Epithalon available in the UK?
Epithalon is available in the UK but is less commonly stocked than NAD+ or GHK-Cu formulations. Treat it as a research chemical rather than a licensed medicine under current UK regulatory conditions, and source it through specialist peptide suppliers rather than mainstream pharmacy channels. Verify that any supplier provides third-party purity certificates and batch documentation before ordering.
Next Steps
Start by identifying your primary research target, whether that is sirtuin-linked DNA repair (NAD+), tissue regeneration (GHK-Cu), metabolic flexibility (MOTS-C), or telomere biology (Epithalon). Once you have selected your peptide, request batch certificates of analysis from at least two UK suppliers and compare purity, lot numbers, and test dates. For pen-format peptides, confirm the per-actuation volume and calculate your expected supply duration based on your intended dosing frequency. If you are considering a stacked protocol, run each compound at its established research dose and maintain detailed dosing records and baseline biomarker measurements before starting. For Epithalon, allow additional time for supplier vetting and import documentation given its research-chemical status in the UK.